Valneva closes in on estimated $500 million chikungunya vaccine market

6 December 2022

French firm Valneva (Euronext Paris: VLA) has presented positive antibody persistence data 12 months after vaccination with a single dose of its chikungunya vaccine candidate, VLA1553.

After reporting positive immunogenicity and safety data from a Phase III study in March of this year, Valneva set up a dedicated antibody persistence trial to monitor a subset of participants for a period of at least five years and hopefully confirm the anticipated long-term durability of the antibody response after a single vaccination.

Antibody persistence prevails

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK